| Term 
 | Definition 
 
        | Constitutive expression in tissues Protein levels are constant Synthesized prostanoids for housekeeping Purposes: gastric protection, kidney function, blood clotting Inhibition leads to GI related side effects |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Express induced by stress, growth factors, cytokines, and inflammatory mediators Sources involve cancer and inflammation Tissue specific effects Inhibition leads to anti-pyretic, analgesic, and anti-inflammatory actions of the NSAIDs Selective inhibition can cause less GI toxicity |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Mild analgesia (MSK pain) Effective where inflammation has sensitized pain receptors Can be additive to opioids Elevates set point of fever in hypothalamus Inflammation, particularly MSK disorders (RA, OA) Symptomatic relief Closure of PDA Chemoprevention |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | GI pain, nausea, diarrhea, hemorrhage, ulcers, perforation Renal insufficiency, failure, hyperkalemia, proteinuria Decreased effecs of anti-hypertensives Decreased excretion due to effect on arterioles (esp ASA) Analgesic nephropathy Selective inhibition of PGI2 (and not TXA) can lead to platelet aggregation Increased gestation and inhibition of labor Post-partum hemorrhage Vasomotor rhinitis Angioneuritic edema Asthma Urticaria, flushing |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | ACE + NSAID + hyperkalemia = bradycardia and syncope Attenuates effects of ACE inhibitors Warfarin - CYP enzymes NSAIDs inhibit metabolism of warfarin - increased propensity for bleeding   |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Often occurs in children Coma, convulsions, cardiovascular collapse Mild headache, dizziness, tinnitus, drowsiness, sweating, thirst, hyperventilation, nausea, vomiting High doses: CNS stimulation and depression, hyperthermia Respiratory alkalosis and eventual acidosis |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Reactive metabolite benzoquinone imine Occurs when gluthione is depleted Single doses 10-15 g Nausea, ab pain, anorexia Serum transaminases can be elevated Hepatic damage occurs at 2-4 days Exacerbated by alcohol and malnutrition Tx: activated charcoal, Mucomyst, supportive care   |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Willowbark Competitive and irreversible inhibitor of COX1 and COX2 Analgesia, Antipyretic at low doses, Anti-inflammatory at high doses, blood thinner, keratolytic, uricosuric Indicated for pain, fever, inflammation, CV disease, UC, gout, RA, cancer Can get Reye's syndrome if given with viral infection First pass metabolism --> salicylate Excreted renally |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | NSAID with no effects on respiratory, CV, GI tract, platelets, coagulation, acid-base status, or uric acid Used for analgesia and fever, but not inflammation Can be combined with opioids Well absored Metabolized by glucuronic acid |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Most commonly used NSAID 2400 mg for inflammation 2 hour half life Indications: PDA closure, topical relief of OA May co-admin with ASA for cardioprotective effects GI effects in 15% |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Single enantiomer NSAID 14 hour half life Used in RA |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Older NSAID that is a stronger analgesic than aspirin Indications: PDA closure, gout, ankylosing spondylitis Opthalmic prep and oral rinse Adverse effects can be more severe |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | NSAID that inhibits leukocyte migration in high doses Absorbed completely Food delays absorption 50 hour half life allows for once daily dosing Indicated for RA |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | A pro-drug NSAID that undergoes enterohepatic cycling Indications: familial polyps, cancers Side effects: Stevens-Johnson syndrome, thrombocytopenia, agranulocytosis, nephrotic syndrome, and liver damage |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | A selective COX2 inhibitor 11 hour half life Has less GI side effects than non-selective NSAIDs Side effects: thrombosis, hypertension, atherogenesis Metabolizes SSRIs Metabolized by microsomal enzymes |  | 
        |  | 
        
        | Term 
 
        | Drugs with Mineralocorticoid activity |  | Definition 
 
        | Aldosterone (only) Cortisol Prednisolone Methylprednisolone Fludrocortisone |  | 
        |  | 
        
        | Term 
 
        | Drugs with Glucocorticoid activity |  | Definition 
 
        | Cortisol Prednisolone (mostly) Methylprednisolone (mostly) Dexamethasone (only) Fludrocortisone |  | 
        |  | 
        
        | Term 
 
        | Features of Mineralocorticoids |  | Definition 
 
        | Influence water and electrolyte balance Made in Zona glomerulosa Does not respond to ACTH stimulus Mineralocorticoid receptors bind aldosterone and glucocorticoids (an enzyme exists to prevent cortisol from binding) |  | 
        |  | 
        
        | Term 
 
        | Features of Glucocorticoids |  | Definition 
 
        | Anti-inflammatory agents that have effects on carbs and protein metabolism Made in Zona fasciculata Responds to ACTH and stress |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Made in zona reticularis Responds to ACTH |  | 
        |  | 
        
        | Term 
 
        | Physiologic Effects of Glucocorticoids |  | Definition 
 
        | Carb and protein metabolism to maintain blood glucose levels Synthesis of glucose, glycogen deposition, protein breakdown, increase of FFA, stimulation of hormones (NE, epi, GH), decrease lymphocytes, eosinophils, monocytes, basophils, decreased lymphoid mass, decrease in TNF Alter immune response of lymphocytes, cytokine releas Decreased prostaglandin and leukotrienes Inhibition of arachidonic acid, leukotrienes, COXs |  | 
        |  | 
        
        | Term 
 
        | Glucocorticoid Toxicity due to Excess |  | Definition 
 
        | HTN, Cushing's syndrome, muscle wasting, HPA suppression, hyperglycemia, immune system syppression, osteoporosis, osteonecrosis, myopathy, cataracts, psychosis, euphoria, growth suppression in children |  | 
        |  | 
        
        | Term 
 
        | Glucocorticoid Toxicity due to Sudden Cessation |  | Definition 
 
        | acute adrenal insufficiency Fever, myalgias, arthritis, malaise Weeks to months recovery with slow taper |  | 
        |  | 
        
        | Term 
 
        | Therapeutic Uses of Glucocorticoids |  | Definition 
 
        | Anti-inflammatory, Immunosuppressive, Rheumatic carditis, Leukemias, SLE, nephrotic syndrome, polyarteritis nodosa, pemphigus, RA, asthma, allergic rhinitis, IBD, stroke and spinal cord injury |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Mineralocorticoid that is produced in the zona glomerulosa that alters Na and water reabsorption in the kidney. Indications: nephrogenic DI |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Endogenous hormone with glucocorticoid and mineralocorticoid activity that works as an anti-inflammatory and immunosuppressant Responds to ACTH and has a negative feedback inhibition to the pituitary and hypothalamus |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Hormone made in opthalmic prep that has mainly glucocorticoid activity with some mineralocorticoid activity. Used in eye inflammation |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Oral prep hormone that has mostly glucocorticoid activity with some mineralocorticoid activity Used as an anti-inflammatory |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Hormone with glucocorticoid activity that can be given as oral, opthalmic, or topical prep Used to diagnose hypercorticism, arthritis, systemic disorders, severe allergies, asthma, and cancers |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Hormone with mostly mineralocorticoid and some glucocorticoid activity that is used to control fluid and electrolyte imbalance Used in Addison's disease |  | 
        |  | 
        
        | Term 
 
        | Mechanisms of Nitroglycerin |  | Definition 
 
        | 1. Relax venous smooth muscle at low doses and arterial smooth muscle at high doses to decrease preload during diastole, increase coronary blood flow 2. Decreases oxygen demand of cardiac muscle by decreasing tension on cardiac walls 3. Dilate epicaridal coronary vessels (preferential to the ones that need oxygen) |  | 
        |  | 
        
        | Term 
 
        | Effects of DHPR Ca Channel Blockers |  | Definition 
 
        | Relaxes smooth muscle at lower concentrations than those required to reduce Ca influex into cardiac cells Generally decreases arterial resistance and BP Reflex increase in CO Decrease coronary resistance Increases coronary blood flow Decreases oxygen demand of myocytes |  | 
        |  | 
        
        | Term 
 
        | Effects of non-DHPR Ca Channel Blockers |  | Definition 
 
        | Less potent vasodilator Decreases HR, contractility, and decreases rate of recovery of Ca channels to slow conduction through AV node Decreases coronary resistance Increases coronary blood flow Decreases oxygen demand of myocytes |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | A non-DHPR Ca Channel blocker Used for angina (esp in individuals with higher HR), SVT, atrial tachycardia, atrial flutter, and atrial fibrillation |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Non-DHPR Ca Channel blocker Used in Angina, SVT, Atrial tachycardia, atrial fibrillation, and atrial flutter It is also a non-specific antagnoist for the SNS to reduce the reflex tachycardia produced by vasodilation |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | A DHPR Ca Channel blocker Used in angina for people with low HR
 Long acting form is much safer Can cause reflex tachycardia (increase HR and contractility) |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | A DHPR Ca Channel blocker Used in variant angina vasospasm It has a high affinity for cerebral vessesl and may reduce vasospasm after subarachnoid hemorrhage |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | A vasodilator Effects: direct relaxation of arterial smooth muscle to reduce TPR Used in Hypertension, especially in pregnancy Contraindicated in patients with HTN and CAD or people > 40 years old Can lead to ischemia because of increase oxygen demand on the heart Should co-administer with sympatholytic like a Beta blocker |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | A vasodilator Effects: direct arteriole relaxation to reduce TPR Also helps grow hair Actives ATP modulated K channels to hyperpolarize the smooth muscle Contraindicated in HTN with LVH Should co-administer with sympatholytic drugs like Beta blockers |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | A vasodilator Effects: arteriole and venule vasodilatin to reduce TPR Also reduces preload to decrease O2 demand on heart Used for hypertensive emergenices and acute MI A prodrug that activates cGMP to reduce contractile state of smooth muscle Metabolized by smooth muscle into nitrous oxide Must be given via IV infusion |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | An Alpha 1 Antagonist Inhibits vasoconstriction induced by catecholamines Effects: Reduces arterial resistance and venous capacitance to reduce TPR Used in HTN First dose phenomenon is common Not effective as a sole treatment for HTN |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | An adrenergic inhibitor that is concentrated in NE vesicles and depletes NE to inhibit the function of postganglionic adrenergic neurons Effects: Reduces sympathetic activation to reduce TPR Adverse effects: postural hypotension, sexual dysfunction, and diarrhea, delayed or retrograde dysfunction Blocks excitation-secretion coupling |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | An adrenergic inhibitor that binds to storage vesicles in central and peripheral adrenergic neurons Inhibits sympathetic effects to reduce TPR Adverse effects: CNS sedation, inability to concentrate, and depression |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | An Alpha 2 Agonist Depletes neuronal stores of NE by blocking feedback mechanisms Reduces sympathetic activity to reduce TPR Can be used for HTN in pregnancy Adverse effects: Hypersensitivity, reduced libido, sedation, depression, blunted sympathetic effects Very difficult drug to tolerate |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | An Alpha 2 Agonist Depletes neuronal stores of NE by blocking feedback mechanisms to reduce TPR High doses also activate alpha 2 receptors in vascular smooth muscle - vasodilation Used for HTN |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | A Beta Blocker Blocks endogenous sympathetic Beta 1 stimulation of the cardiac SA node and ventricular muscle Effects: reduces myocarial contractility, reduces cardiac output, and decreases renin and ANG II levels Used for HTN, angina, and arrhythmias African Americans can have a lesser response Side effects: ED, depression, insomnia Contraindicated in asthma Decreases mortality after MI |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | A DHPR Calcium Channel blocker used in HTN Reduces vascular resistance and BP by decreases influx of Ca into arterial smooth muscle cells and cardiac myocytes Special population: HTN in low HR and AA Angina, arrhythmias Long acting is best |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | A diuretic that inhibits Na-Cl cotransport in the distal tubule Decreases blood volume, reduces preload, SV, and CO Long term use decreases vascular resistance Used in HTN Adverse effects: impotence, hypokalemia Drug interaction: quinidine |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | A K sparing diuretic that blocks Na channels in the collecting duct Decreases BV, reduces preload, SV, and CO Long term use decreases vascular resistance Used in HTN along with a thiazide diuretic like hydrochlorothiazide |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | An ACE inhibitor that reduces aldosterone secretion Reduces vasoconstriction and decreases Na retention Used in HTN, LVH regression, delay of progression of heart failure and MI, especially good for diabetics Adverse effects: cough, teratogenic, decreases GFR (do not use in renal failure) Does not invoke a reflex tachycardia |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | An ARB that maintains bradykinin levels Reduces vasoconstriction and decreases Na retention Used in HTN but is not shown to be particularly helpful in special populations Contraindicated in pregnancy |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | An ester local anesthetic that has a shorter duration of action Used for topical pain, especially eye surgery Adverse effects: HTN, tachycardia, arrhythmias, and vasoconstriction Metabolized by plasma and liver pseudocholinesterases Has a high abuse potential May produce allergies - PABA |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | An ester local anesthetic that has shorter duration of action Used mostly for infiltration and peripheral nerve blocks Has a low systemic toxicity Also known as Novocaine May cause allergies - PABA |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | An amide local anesthetic that has a rapid onset and longer duration of action Used for pain and arrhythmias Combine with epinephrine to prevent vasodilation Metabolized by microsomal enzymes Most commonly used local anesthetic |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | An amide local anesthetic with rapid onset and longer duration of action Has lower cardiac effects than some other local anesthetics Exists in S-isoform |  | 
        |  | 
        
        | Term 
 
        | Carbon monoxide poisoning |  | Definition 
 
        | Poison that blocks oxygen transport Route: inhalation Classic sx: pink flushed skin Antidote: high partial pressure O2 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Poison that blocks oxygen transport systems Sources: nitrates, aromatics, and nitro compounds Mechanism: Ferric iron (Fe3) binds to hemoglobin Classic Sx: chocolate brown blood Antidote: methylene blue |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Poison that alters enzyme activity Mechanism: blocks cytochrome oxidase Sx: CNS effects, mydriasis, cyanosis, systemic sx Antidote: 1. methemoglobin formation with amylnitrate and NaNO, 2. inactivation of poisoning with sodium thiosulfate |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Poison that alters enzyme activity Source: insecticide inhalants (used for lice) Mechanism: phosphorylates AChesterase Cholinergic crisis causes vomiting, tremors, lethargy, ab pain, fasisculations, headache, SLUD, and mioisis Antidote 1. Block ACh with atropine 2. Reactive AChesterase with Pralidoxine Also renders it inert |  | 
        |  | 
        
        | Term 
 
        | Solvent poisoning (Kerosene, Gasoline, Diesel, Paint Thinner) |  | Definition 
 
        | Poison that alters membranes Route: inhalation and ingestion Causes CNS depression, V-Fib, and at risk for aspiration Antidote: supportive care and possibly cathartics Do not induce emesis or lavage |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | A heavy metal poison that alters membranes Route: ingestion Mechanisms: iron sites get saturated, can be corrosive to the GI tract Can cause hepatic dysfunction and permanent bowel obstruction Antidote: deferoxamine chelating agent |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Heavy metal poisoning that can alter membranes Routes: elemental via ingestion, ionic/inorganic via inhalation Mechanisms: targets the CNS, kidneys Organic version can be bioaccumulated in foods Can cause erethism (felt hats) Temporary blindness and red spots Antidote: BAL (dimercaprol) chelating agent |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Heavy metal poison that alters membranes Routes: ingestion, exposure Can lead to developmental learning disabilites Antidote: calcium disodium (EDTA) |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Heavy metal poison that alters membranes Routes: industrial exposure Can cause lung damage (alpha AT dysfunction), osteomalacia, immunosuppressant, growth retardation, carcinogen Has a very long half life Antidote: Calcium disodium (EDTA) |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Poison that alters membranes Routes: inhalation, ingestion, dermal, and ocular Ex: battery |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Free radical poison Routes: inhalation, percutaneous absorption, ingestion Effects: nausea, vomiting, dizziness, headache, stupor, convulsions, coma, death, CNS depression, medullary depression, V-Fib Ingestion can cause ab pain, hematemesis, and hepatic damage |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Reactive oxygen species that is used as an herbicide Effects: lung toxicity, vomiting, burning pain in the mouth, throat, and lethargy Tx: dialysis |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Nerve fiber that releases glutamate into the dorsal horn Fibers are myelinated Send a quick propagation of the AP Produces a fast onset, intense pain that subsides quickly |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Nerve fibers that release Substance P into the dorsal horn The nerve fibers are unmyelinated Slow propagation of the AP Produces a later dull pain that lasts a long time Another effect causes mast cell degranulation and histamine release leading to vasodilation, immune cell release, inflammation, and further pain |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Cocaine Procaine Tetracaine Benzocaine |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Lidocaine Mepivacaine Bupivacaine Etidocaine Prilocaine Ropivacaine |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | The inherent capacity of a substance to produce injury Estimated by LD50 |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Practical certainty that injury will occur when a substance is used in a stated quantity and set of conditions Also known as proportionate risk |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Practical certainty that injury will not occur when a substance is used in a stated quantity and set of conditions Also known as acceptable risk |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | Assessment to determine amount and conditions that can be used without appreciable risk of injury. Affected by route of exposure (inhalation, ingestion), duration of exposure (acute or chronic), and the presence of mixtures (what the chemical is) |  | 
        |  |